An update for general dental practitioners on a new medication for the management of patients with haemophilia A
Autor: | Stephanie Fenesan, Bella Madan, Najla Nizarali |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Dental Update. 49:477-480 |
ISSN: | 2515-589X 0305-5000 |
DOI: | 10.12968/denu.2022.49.6.477 |
Popis: | Emicizumab is a new medication used in the treatment of people with haemophilia A and there is little in the current literature providing guidance for dental treatment. It is important to risk assess dental procedures appropriately according to their bleeding risk and to liaise closely with the patient's haematology team. This article provides an overview of emicizumab, its mechanism of action and implications for dental treatment, as well as examples of surgical management plans provided by the haemophilia team. CPD/Clinical Relevance: It is important to liaise closely with the patient's haemophilia team to ensure provision of safe dental treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |